Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Clinical trial NCT06162221 · RECRUITING

Trial details

NCT number: NCT06162221
Sponsor: Revolution Medicines, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer, NSCLC KRAS, NRAS, HRAS-mutated NSCLC KRAS G12C-mutated Solid Tumors, Lung Cancer Lung Cancer Stage IV, Advanced Solid Tumor, Cancer RAS G12D-mutated NSCLC

Start date: 2024-01-18
Primary completion: 2027-06-01
Enrollment: 616

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.